Share on LinkedInShare on LinkedIn

ARTICLE · 13 JUNE 2012

DIP Working Group Recommends That PMPRB Permanently Adopt The DIP Methodology

On May 16, 2012, a Report setting out the follow-up recommendations of the DIP Working Group on the pilot implementation of the DIP Methodology was released by the PMPRB.

CanadaFood, Drugs, Healthcare, Life Sciences

On May 16, 2012, a Report setting out the follow-up recommendations of the DIP Working Group (DIP-WG) on the pilot implementation of the DIP Methodology was released by the PMPRB. In its report, the DIP-WG recommended that the Board adopt the DIP Methodology on a permanent basis.

The DIP Methodology was introduced to address situations where the price of a patented medicine increases in excess of that allowable under the CPI-Adjustment Methodology due to a reduction or termination of benefits to customers (i.e., any reduction given as a promotion or in the form of rebates, discounts, refunds, free goods, free services, gifts or any other benefits of a like nature). Under the DIP Methodology, when a Market-Specific Average Transaction Price of a drug product increases by more than that allowable under the CPI-Adjustment Methodology and the patentee provides the required evidence, the price of the drug product may increase up to the highest Non-Excessive Average Price

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from